CohBar, Inc. - Special Call Transcript
Good afternoon, and welcome to the CohBar KOL call. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the CohBar website following the event.
I'd now like to turn the call over to your host, Steve Engle, Chief Executive Officer of CohBar. Please go ahead, sir.
Thank you, Sarah. Welcome, everyone. Thank you for joining us. CohBar is developing compounds based on breakthrough mitochondrial science that represents a major new source of therapeutics for multiple diseases. Today, we are very pleased to discuss our novel Antifibrotic Peptides for IPF and other fibrotic diseases. And with the help of Dr. Maher, who is a world-class medical expert and clinical trialist, the need for new approaches in idiopathic pulmonary fibrosis.
Next slide, please. Forward-looking statements apply.
Next slide, please. CohBar is the leader in developing a new class therapeutics -- mitochondrial-based therapeutics. Our Chief Science Officer, Ken
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
